| Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. Johnson K.B., Petersen-Jones H., Thompson J.M., Hitomi K., Itoh M., Bakker E.N., Johnson G.V., Colak G., Watts S.W.
Am. J. Physiol. Heart Circ. Physiol. 302:H1355-66(2012) · Mapped (2) |
| Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Colak G., Johnson G.V.
Neurobiol. Dis. 45:1042-1050(2012) · Mapped (2) |
| Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. Dolan P.J., Jin Y.N., Hwang W., Johnson G.V.
FEBS Lett. 585:3424-3429(2011) · Mapped (19) |
| Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. Quintanilla R.A., Dolan P.J., Jin Y.N., Johnson G.V.
Neurobiol. Aging 33:619.e25-35(2012) · Mapped (16) |
| The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. Pritchard S.M., Dolan P.J., Vitkus A., Johnson G.V.
J. Cell. Mol. Med. 15:1621-1635(2011) · Mapped (6) |
| Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. Colak G., Keillor J.W., Johnson G.V.
PLoS ONE 6:e16665-e16665(2011) · Mapped (8) |
| Differential modulation of TCF/LEF-1 activity by the soluble LRP6-ICD. Beagle B., Johnson G.V.
PLoS ONE 5:e11821-e11821(2010) · Mapped (14) |
| A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. Dolan P.J., Johnson G.V.
J. Biol. Chem. 285:21978-21987(2010) · Mapped (5) |
| Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/beta-catenin pathway and attenuate GSK3beta activity. Beagle B., Mi K., Johnson G.V.
J. Cell. Biochem. 108:886-895(2009) · Mapped (17) |
| Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. Quintanilla R.A., Matthews-Roberson T.A., Dolan P.J., Johnson G.V.
J. Biol. Chem. 284:18754-18766(2009) · Mapped (5) |
| Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Kong P.J., Kil M.O., Lee H., Kim S.S., Johnson G.V., Chun W.
Neurol. Res. 31:77-83(2009) · Mapped (5) |
| Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. Quintanilla R.A., Jin Y.N., Fuenzalida K., Bronfman M., Johnson G.V.
J. Biol. Chem. 283:25628-25637(2008) · Mapped (11) |
| Histone deacetylase 6 interacts with the microtubule-associated protein tau. Ding H., Dolan P.J., Johnson G.V.
J. Neurochem. 106:2119-2130(2008) · Mapped (18) |
| Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. Filiano A.J., Bailey C.D., Tucholski J., Gundemir S., Johnson G.V.
FASEB J. 22:2662-2675(2008) · Mapped (8) |
| Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage. Chun W., Waldo G.S., Johnson G.V.
J. Neurochem. 103:2529-2539(2007) · Mapped (10) |
| Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. Chun W., Johnson G.V.
J. Biol. Chem. 282:23410-23417(2007) · Mapped (10) |
| Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. Ruan Q., Quintanilla R.A., Johnson G.V.
J. Neurochem. 102:25-36(2007) · Mapped (12) |
| Regulated proteolytic processing of LRP6 results in release of its intracellular domain. Mi K., Johnson G.V.
J. Neurochem. 101:517-529(2007) · UniProtKB (1) · Mapped (5) |
| Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Clodfelder-Miller B.J., Zmijewska A.A., Johnson G.V., Jope R.S.
Diabetes 55:3320-3325(2006) · Mapped (5) |
| Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. Milakovic T., Quintanilla R.A., Johnson G.V.
J. Biol. Chem. 281:34785-34795(2006) · Mapped (4) |
| Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. Ding H., Matthews T.A., Johnson G.V.
J. Biol. Chem. 281:19107-19114(2006) · Mapped (6) |
| The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. Mi K., Dolan P.J., Johnson G.V.
J. Biol. Chem. 281:4787-4794(2006) · Mapped (10) |
| Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. Milakovic T., Johnson G.V.
J. Biol. Chem. 280:30773-30782(2005) · Mapped (2) |
| 14-3-3Zeta does not increase GSK3beta-mediated tau phosphorylation in cell culture models. Matthews T.A., Johnson G.V.
Neurosci. Lett. 384:211-216(2005) · Mapped (10) |
| Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. Bailey C.D., Johnson G.V.
J. Neurochem. 92:83-92(2005) · Mapped (6) |
